Go Back
  • For Business
  • |
  • Warnings
  • Data Suite
  • Newsletters
  • Advertising
  • Superior Accuracy™
Sweltering 90-100 F heat to expand, affect 170 million in central and eastern US. Details here Chevron right
Severe storms sweep Northeast, teen struck by lightning in Central Park. Read more Chevron right

Ashburn, VA

90°F
Location Chevron down
Location News Videos
Use Current Location
Recent

Ashburn

Virginia

90°
No results found.
Try searching for a city, zip code or point of interest.
settings
Ashburn, VA Weather
Today WinterCast Local {stormName} Tracker Hourly Daily Radar MinuteCast Monthly Air Quality Health & Activities

Around the Globe

Hurricane Tracker

Severe Weather

Radar & Maps

News

News & Features

Astronomy

Business

Climate

Health

Recreation

Sports

Travel

For Business

Warnings

Data Suite

Newsletters

Advertising

Superior Accuracy™

Video

Winter Center

AccuWeather Early Hurricane Center Top Stories Trending Today Astronomy Heat Climate Health Recreation In Memoriam Case Studies Blogs & Webinars

News / Health

FDA approves Novavax's COVID-19 vaccine with limitations

The Novavax COVID-19 vaccine has had emergency use authorization since 2022, and an updated version was approved in August. The brand name is Nuvaxovid.

By Allen Cone, UPI

Published May 19, 2025 11:18 AM EDT | Updated May 19, 2025 11:19 AM EDT

Copied

Partner Content

UPI

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. (File Photo by Jim Lo Scalzo/EPA-EFE)

May 18 (UPI) -- The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

The agency approved the vaccine only for people 65 and older and those 12 and older with at least one underlying condition in which they are at a higher risk of severe illness. The company is based in Gaithersburg, Md.

The conditions include older age, asthma, diabetes, lung disease, obesity and pregnancy.

"Market research and US CDC statistics indicate that older individuals and those with underlying conditions are the populations most likely to seek out COVID-19 vaccination seasonally," Novavax President and CEO John Jacobs said in a statement Saturday to CNN.

"This significant milestone demonstrates our commitment to these populations and is a significant step towards availability of our protein-based vaccine option."

The Novavax COVID-19 vaccine has had emergency use authorization since 2022, and an updated version was approved in August. The brand name is Nuvaxovid.

The FDA granted Pfizer-BioNTech full approval for those 12 and older in August 2021 and Moderna in January 2022. They remain available under emergency use authorization for children as young as 6 months.

Novavax uses more traditional protein-based technology than the mRNA vaccines of Pfizer and Moderna.

Pfizer was the first COVID-19 vaccine to receive emergency approval in December 2020 and Moderna was followed one week later.

The first Covid-19 case was reported in the United States on Jan. 20, 2020.

The CDC no longer tracks cases but examines SARS-CoV-2 levels in sewage, and limited data from hospitals and states. Cases now are hard to track because most people get tests at home and the results are not reported to state health agencies.

About 23% of U.S. adults are estimated to be up to date with the vaccine, according to the CDC through April. For children 6 months and up to 18, it is an estimated 13.% the CDC reported.

With Robert F. Kennedy Jr., a vaccine skeptic, leading Health and Human Services, the FDA and CDC are giving greater scrutiny to the shots.

The FDA delayed the decision on the vaccine as it sought more data, a source told CNN.

In the approval letter issued Friday, Novavax must conduct post-marketing studies looking at the risk of myocarditis and pericarditis in people who receive the vaccine. These are inflammation of the heart muscle and of the membrane surrounding the heart.

Only a few cases were reported in the 30,000-person clinical of the Novavax vaccine, the CDC notes. But the CDC and its Advisory Committee on Immunization Practices have said the benefits of the vaccination outweigh the rare risk of heart inflammation in all groups recommended for vaccination.

The CDC is considering whether to only recommend yearly vaccines for older people or ones with a compromised immune function. Everyone 6 months of age and older are now recommended to get the yearly dose.

Read more:

New 'long COVID' study zeroes in on possible cause of brain fog
What to know about fluoride in drinking water
US surpasses 1,000 measles cases in 2025
Report a Typo

Weather News

Severe Weather

Juneau, Alaska gets rare 'tornado' and severe thunderstorm

Jun. 20, 2025
Recreation

Lightning strikes hikers, prompts record rescue on Colorado mountain

Jun. 19, 2025
Weather Forecasts

Major cooldown eyes West as fire weather increases for Great Basin

Jun. 21, 2025
Show more Show less Chevron down

Topics

AccuWeather Early

Hurricane Center

Top Stories

Trending Today

Astronomy

Heat

Climate

Health

Recreation

In Memoriam

Case Studies

Blogs & Webinars

Top Stories

Weather Forecasts

Sweltering 90-100 F heat to expand, affect 170 million in US

37 minutes ago

Severe Weather

Storms sweep Northeast, teen struck by lightning in Central Park

1 day ago

Severe Weather

Severe storms to continue riding edge of heat dome into new week

36 minutes ago

Astronomy

Meteorological summer vs. astronomical summer explained

5 days ago

Astronomy

NASA raises chance for asteroid to hit moon

1 day ago

More Stories

Featured Stories

Astronomy

Summer solstice: Everything to know about the year's longest day

1 day ago

Health

‘Nimbus’ COVID-19 variant arrives in U.S. after China surge

1 day ago

Severe Weather

Rare high-elevation tornado confirmed at Pikes Peak

2 days ago

Weather News

First methane-powered sea spiders found crawling on the ocean floor

3 days ago

Weather News

‘Dragon Man’ DNA revelation puts a face to group of ancient humans

1 day ago

AccuWeather Health FDA approves Novavax's COVID-19 vaccine with limitations
Company
Proven Superior Accuracy About AccuWeather Digital Advertising Careers Press Contact Us
Products & Services
For Business For Partners For Advertising AccuWeather APIs AccuWeather Connect RealFeel® and RealFeel Shade™ Personal Weather Stations
Apps & Downloads
iPhone App Android App See all Apps & Downloads
Subscription Services
AccuWeather Premium AccuWeather Professional
More
AccuWeather Ready Business Health Hurricane Leisure and Recreation Severe Weather Space and Astronomy Sports Travel Weather News Winter Center
Company
Proven Superior Accuracy About AccuWeather Digital Advertising Careers Press Contact Us
Products & Services
For Business For Partners For Advertising AccuWeather APIs AccuWeather Connect RealFeel® and RealFeel Shade™ Personal Weather Stations
Apps & Downloads
iPhone App Android App See all Apps & Downloads
Subscription Services
AccuWeather Premium AccuWeather Professional
More
AccuWeather Ready Business Health Hurricane Leisure and Recreation Severe Weather Space and Astronomy Sports Travel Weather News Winter Center
© 2025 AccuWeather, Inc. "AccuWeather" and sun design are registered trademarks of AccuWeather, Inc. All Rights Reserved.
Terms of Use | Privacy Policy | Cookie Policy | About Your Privacy Do Not Sell or Share My Personal Information

...

...

...